Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Teva
Federal Trade Commission
Queensland Health
US Department of Justice
McKesson
US Army
Healthtrust
QuintilesIMS
Cantor Fitzgerald

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022418

« Back to Dashboard

NDA 022418 describes FIBRICOR, which is a drug marketed by Aralez Pharms Inc and is included in one NDA. It is available from six suppliers. There are four patents protecting this drug. Additional details are available on the FIBRICOR profile page.

The generic ingredient in FIBRICOR is fenofibric acid. There are four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the fenofibric acid profile page.
Summary for 022418
Tradename:FIBRICOR
Applicant:Aralez Pharms Inc
Ingredient:fenofibric acid
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 022418
Suppliers and Packaging for NDA: 022418
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FIBRICOR fenofibric acid TABLET;ORAL 022418 NDA AR Scientific, Inc. 13310-101 13310-101-90 90 TABLET in 1 BOTTLE, PLASTIC (13310-101-90)
FIBRICOR fenofibric acid TABLET;ORAL 022418 NDA AR Scientific, Inc. 13310-101 13310-101-03 250 TABLET in 1 BOTTLE, PLASTIC (13310-101-03)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength35MG
Approval Date:Aug 14, 2009TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Aug 20, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
Patent:➤ SubscribePatent Expiration:Aug 20, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
Patent:➤ SubscribePatent Expiration:Aug 20, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Express Scripts
Harvard Business School
Teva
Cerilliant
Healthtrust
AstraZeneca
Merck
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot